EDP Sciences logo
Subscriber Authentication Point
Search
Menu
Home All issues Volume 35 / No 12 (Décembre 2019) Med Sci (Paris), 35 12 (2019) 1137-1145 References
Open Access
Issue
Med Sci (Paris)
Volume 35, Number 12, Décembre 2019
Anticorps monoclonaux en thérapeutique
Page(s) 1137 - 1145
Section Les anticorps biosimilaires
DOI https://doi.org/10.1051/medsci/2019214
Published online 06 January 2020
  1. Guidelines on evaluation of similar biotherapeutic products 5SBPs, 2010; p. 1–34. [Google Scholar]
  2. European Medecines Agency cfMpfHU. Guideline on similar biological medecinal products containing monoclonal antibodies - non clinical and clinical issues. http://wwwemaeuropaeu/docs/en_GB/document_library/Scientif_guideline/2012/06/WC500128686pdf. 2012. [Google Scholar]
  3. Agency EM. Guideline on similar biological products containing biotechnology-derived proteins as active sustance: non-clinical and clinical issues. http://wwwemaeuropaeu/docs/en_GB/document_library/Scientif_guideline/2015/01/WC500180219pdf. 2015. [Google Scholar]
  4. Agencies UEM. Scientific considerations in demonstrating biosimilarity to a reference product, Guidance for Industry. http://wwwfdagov/downloads/drugs/guidanceComplianceRegulatoryInformation/Guidances/UCM291128pdf. 2015. [Google Scholar]
  5. Vezér B, Buzás Z, Sebeszta M, Zrubka Z. Authorized manufacturing changes for therapeutic monoclonal antibodies (mAbs) in European Public Assessment Report (EPAR) documents. Curr Med Res Opin 2016 ; 32: 829–834. [CrossRef] [PubMed] [Google Scholar]
  6. Jorgensen KK, Olsen IC, Goll GL, et al. Switching from originatoir infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab [NOR-SWITCH]: a 52-week, randomised, double-blind, non-inferiority trial. Lancet 2017 ; 389: 2304–2316. [CrossRef] [PubMed] [Google Scholar]
  7. Glintborg B, Sørensen IJ, Loft AG, et al. A nationwide non-medical switch from originator infliximab to biosimilar CT-P13 in 802 patients with inflammatory arthritis: 1-year clinical outcomes from the DANBIO registry. Ann Rheum Dis 2017 ; 76: 1426–1431. [CrossRef] [PubMed] [Google Scholar]
  8. Agence Nationale de sécurité du médicament et des produits de santé. État des lieux sur les médicaments biosimilaires. Paris: Ansm, 2016: 1–28. [Google Scholar]
  9. ANSM. Analyse des ventes de médicaments en France en 2013; 2014; p. 1–36 [http://www.ansm.sante.fr/content/download/64305/824219/version/2/file/ANSM.Analyse-Ventes-Medicaments.2013.pdf]. [Google Scholar]
  10. Ghersinick-09072. In: Dépenses de médicaments de l’année 2014 et du premier semestre 2015. Paris: Caisse nationale d’assurance maladie, 2015: 1–24. [Google Scholar]
  11. Yoo DH, Prodanovic N, Jaworski J, et al. Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension study. Ann Rheum Dis 2017 ; 76: 355–363. [CrossRef] [PubMed] [Google Scholar]
  12. Park W, Yoo DH, Miranda P, et al. Efficacy and safety of switching from reference infliximab to CT-P13 compared with maintenance of CT-P13 in ankylosing spondylitis: 102-week data from the PLANETAS extension study. Ann Rheum Dis 2017 ; 76: 346–354. [CrossRef] [PubMed] [Google Scholar]
  13. Avouac J, Moltó A, Abitbol V, et al. Systematic switch from innovator infliximab to biosimilar infliximab in inflammatory chronic diseases in daily clinical practice: The experience of Cochin University Hospital, Paris. France. Semin Arthritis Rheum 2018 ; 47: 741–748. [CrossRef] [Google Scholar]
  14. Scherlinger M, Germain V, Labadie C, et al. FHU ACRONIM. Switching from originator infliximab to biosimilar CT-P13 in real-life: the weight of patient acceptance. Joint Bone Spine 2018 ; 85: 561–567. [CrossRef] [PubMed] [Google Scholar]
  15. Arrêté du 3 août 2018 relatif à l’expérimentation pour l’incitation à la prescription hospitalière de médicaments biologiques similaires délivrés en ville. Journal Officiel 17 août 2018. [Google Scholar]
  16. Arrêté du 12 février 2019 relatif à l’expérimentation pour l’incitation à la prescription hospitalière de médicaments biologiques similaires délivrés en ville. Journal Officiel 15 février 2019. [Google Scholar]
  17. Hortobagyi GN. Trastuzumab in the treatment of breast cancer. N Engl J Med 2005 ; 353: 1734–1736. [Google Scholar]
  18. Pivot X, Aulagner G, Blay JY, et al. Challenges in the implementation of trastuzumab biosimilars: an expert panel’s recommendations. Anticancer Drugs 2015 ; 26: 1009–1016. [CrossRef] [PubMed] [Google Scholar]
  19. Hurst S, Ryan AM, Ng CK, et al. Comparative nonclinical assessments of the proposed biosimilar PF-05280014 and trastuzumab (Herceptin®). BioDrugs 2014 ; 28: 451–459. [CrossRef] [PubMed] [Google Scholar]
  20. Pivot X, Curtit E, Lee YJ, et al. A Randomized phase I pharmacokinetic study comparing biosimilar candidate SB3 and trastuzumab in healthy male subjects. Clin Ther 2016; 38: 1665–73e3. [CrossRef] [PubMed] [Google Scholar]
  21. Pivot X, Deslypere JP, Park LS, Kim MJ, Lee W, Lee J. A randomized phase I study comparing the pharmacokinetics of HD201, a trastuzumab biosimilar, with European Union-sourced herceptin. Clin Ther 2018 ; 40: 396–405 e4. [Google Scholar]
  22. Esteva FJ, Stebbing J, Wood-Horrall RN, Winkle PJ, Lee SY, Lee SJ. A randomised trial comparing the pharmacokinetics and safety of the biosimilar CT-P6 with reference trastuzumab. Cancer Chemother Pharmacol 2018 ; 81: 505–514. [CrossRef] [PubMed] [Google Scholar]
  23. Hanes V, Chow V, Zhang N, Markus R. A randomized, single-blind, single-dose study evaluating the pharmacokinetic equivalence of proposed biosimilar ABP 980 and trastuzumab in healthy male subjects. Cancer Chemother Pharmacol 2017 ; 79: 881–888. [CrossRef] [PubMed] [Google Scholar]
  24. Morita J, Tanaka M, Nomoto M, et al. Pharmacokinetic bioequivalence, safety, and immunogenicity of DMB-3111, a trastuzumab biosimilar, and trastuzumab in healthy Japanese adult males: results of a randomized trial. BioDrugs 2016 ; 30: 17–25. [CrossRef] [PubMed] [Google Scholar]
  25. Zhou X, Yu J, Wang W, et al. A phase I dose-escalation study of a biosimilar trastuzumab in Chinese metastasis breast cancer patients. Springerplus. 2015 ; 4: 803. [CrossRef] [PubMed] [Google Scholar]
  26. Yin D, Barker KB, Li R, et al. A randomized phase 1 pharmacokinetic trial comparing the potential biosimilar PF-05280014 with trastuzumab in healthy volunteers (REFLECTIONS B327–01). Br J Clin Pharmacol 2014 ; 78: 1281–1290. [CrossRef] [PubMed] [Google Scholar]
  27. Wisman LA, De Cock EP, Reijers JA, et al. A phase I dose-escalation and bioequivalence study of a trastuzumab biosimilar in healthy male volunteers. Clin Drug Investig 2014 ; 34: 887–894. [Google Scholar]
  28. Bruno R, Washington CB, Lu JF, Lieberman G, Banken L, Klein P. Population pharmacokinetics of trastuzumab in patients with HER2+ metastatic breast cancer. Cancer Chemother Pharmacol 2005 ; 56: 361–369. [CrossRef] [PubMed] [Google Scholar]
  29. Leyland-Jones B, Gelmon K, Ayoub JP, et al. Pharmacokinetics, safety, and efficacy of trastuzumab administered every three weeks in combination with paclitaxel. J Clin Oncol 2003 ; 21: 3965–3971. [CrossRef] [PubMed] [Google Scholar]
  30. von Minckwitz G, Colleoni M, Kolberg HC, et al. Efficacy and safety of ABP 980 compared with reference trastuzumab in women with HER2-positive early breast cancer (LILAC study): a randomised, double-blind, phase 3 trial. Lancet Oncol 2018 ; 19: 987–998. [CrossRef] [PubMed] [Google Scholar]
  31. Stebbing J, Baranau Y, Baryash V, et al. CT-P6 compared with reference trastuzumab for HER2-positive breast cancer: a randomised, double-blind, active-controlled, phase 3 equivalence trial. Lancet Oncol 2017 ; 18: 917–928. [CrossRef] [PubMed] [Google Scholar]
  32. Pivot X, Bondarenko I, Nowecki Z, et al. Phase III, randomized, double-blind study comparing the efficacy, safety, and Immunogenicity of SB3 (trastuzumab biosimilar) and reference trastuzumab in patients treated with neoadjuvant therapy for human epidermal growth factor receptor 2-positive early breast cancer. J Clin Oncol 2018 ; 36: 968–974. [CrossRef] [PubMed] [Google Scholar]
  33. Lammer P, Dank M, Masetti R, et al. Neoadjuvant PF-05280014 (a potential trastuzumab biosimilar) versus trastuzumab for operable HER2+ breaast cancer. Br J Cancer 2018 ; 119: 266–273. [CrossRef] [PubMed] [Google Scholar]
  34. Pivot X, Thierry-Vuillemin A, Villanueva C, Bazan F. Response rates: a valuable signal of promising activity?. Cancer J 2009 ; 15: 361–365. [CrossRef] [PubMed] [Google Scholar]
  35. Cortazar P, Zhang L, Untch M, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet. 2014 ; 384: 164–172. [CrossRef] [PubMed] [Google Scholar]
  36. Pivot X, Cox DG. A new era for treatment development in HER2-positive breast cancer. Lancet Oncol 2018 ; 19: 160–162. [CrossRef] [PubMed] [Google Scholar]
  37. Rugo HS, Barve A, Waller CF, et al. Effect of a proposed trastuzumab biosimilar compared with Trastuzumab on Overall Response Rate in Patients With ERBB2 (HER2)-Positive Metastatic Breast Cancer: A Randomized Clinical Trial. JAMA 2017 ; 317: 37–47. [CrossRef] [PubMed] [Google Scholar]
  38. Pegram M, Tan-Chui E, Freyman A, et al. A randomized, double blind study of PF-05280014 (a potential trastuuzmab biosimilar) vs trastuzumab, both in combination with paclitaxel, as first-line treatment for HER2-positive metastatic breast canecr. European Society forMedical Oncology (ESMO). 2017. [Google Scholar]
  39. Pivot X, Bondarenko I, Nowecki Z, et al. A phase III study comparing SB3 (a proposed trastuzumab biosimilar) and trastuzumab reference product in HER2-positive early breast cancer treated with neoadjuvant-adjuvant treatment: final safety, immunogenicity and survival results. Eur J Cancer 2018 ; 93: 19–27. [CrossRef] [PubMed] [Google Scholar]
  40. Kim S, Song J, Park S, et al. Drifts in ADCC-related quality attributes of Herceptin(R): Impact on development of a trastuzumab biosimilar. MAbs 2017 ; 9: 704–714. [CrossRef] [PubMed] [Google Scholar]
  41. Pivot X, Petit T. Can we establish a hierarchy among trastuzumab biosimilar candidates?. Br J Cancer 2018 ; 119: 263–265. [CrossRef] [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.